Aquestive Therapeutics, Inc. Share Price & Technical Analysis
AQST · $4.12 (-2.60%)
Healthcare / Drug Manufacturers - Specialty & Generic
$4.12
-2.60%
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulatio…
Price chart
Seasonality
May has 1 positive and 3 negative years (last 5 years shown)
0% return in May, 19% avg return in past 3 year May month.
-49% return in 2026, 96% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -54% | 0% | 8% | -2% | 0% | – | – | – | – | – | – | – | -49% |
| 25 | -17% | -7% | 4% | 0% | -7% | 22% | 15% | 0% | 47% | 21% | -9% | 7% | 77% |
| 24 | 20% | 48% | 16% | -21% | -12% | -13% | 46% | 18% | 14% | 10% | -9% | -31% | 86% |
| 23 | 0% | -11% | 38% | 18% | 77% | -30% | 38% | -30% | -6% | 7% | 38% | -13% | 123% |
| 22 | -32% | 0% | -10% | -48% | -29% | -40% | 33% | 75% | -14% | -25% | 0% | 0% | -91% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$530.70M
P/E ratio
—
52W high
$7.55
52W low
$2.38
Volume
8,93,169
Beta
1.50
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Aquestive Therapeutics, Inc. share price today?
- Aquestive Therapeutics, Inc. (AQST) last traded around $4.12 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does AQST have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for AQST. Download the app for real-time alerts.
- How can I analyze Aquestive Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.